glp-1 patent Ozempic, Wegovy and Rybelsus: The patents behind Novo Nordisk's weight-loss drugs Ozempic's patent problem: how Novo

An oral formulation of semaglutide exists (branded as Rybelsus)

Glia 39(1):8597 Lee CH, Jeon SJ, Cho KS, Jeon SJ, Cho KS, Moon E, Sapkota A, Jun HS, Ryu JH, Choi JW (2018) Activation of glucagon-like peptide-1 receptor promotes neuroprotection in experimental autoimmune encephalomyelitis by reducing neuroinflammatory responses

Gabriel FC, Oliveira M, Martella BDM, Berk M, Brietzke E, Jacka FN, et al

Remember, these drugs are temporary solutions and tools you can use to help with your weight loss journey.

The CDC recommends at least two days a week of muscle-strengthening activities for general health, but for those on semaglutide, it is a critical tool for maintaining long-term weight loss

For years, patients searching for effective, science-backed treatment had limited options: in-person clinics with long wait times, primary care physicians reluctant to prescribe newer medications, or expensive out-of-pocket programs